•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Briacell Therap (NASDAQ:BCTX) Shares Break Above 200 Day Moving Average – Should You Sell?
BriaCell Therapeutics (TSE:BCT) Share Price Breaks Above 200-Day Moving Average – Here’s Why
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell Awarded 2026 “Immunotherapy Solution of the Year” By BioTech Breakthrough
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
BriaCell Therapeutics Announces Closing of Offering
BriaCell Presents Positive Clinical Data at ASCO 2026
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
Already premium?